- Home
- EPSM vs ADAP Comparison
EPSM vs ADAP Comparison
Compare EPSM & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPSM
- ADAP
- Stock Information
- Founded
- EPSM 2010
- ADAP 2008
- Country
- EPSM China
- ADAP United Kingdom
- Employees
- EPSM N/A
- ADAP N/A
- Industry
- EPSM
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- EPSM
- ADAP Health Care
- Exchange
- EPSM Nasdaq
- ADAP Nasdaq
- Market Cap
- EPSM 71.3M
- ADAP 71.6M
- IPO Year
- EPSM 2025
- ADAP 2015
- Fundamental
- Price
- EPSM $4.95
- ADAP $0.31
- Analyst Decision
- EPSM
- ADAP Strong Buy
- Analyst Count
- EPSM 0
- ADAP 5
- Target Price
- EPSM N/A
- ADAP $1.83
- AVG Volume (30 Days)
- EPSM 577.3K
- ADAP 2.8M
- Earning Date
- EPSM 01-01-0001
- ADAP 05-14-2025
- Dividend Yield
- EPSM N/A
- ADAP N/A
- EPS Growth
- EPSM N/A
- ADAP N/A
- EPS
- EPSM 0.05
- ADAP N/A
- Revenue
- EPSM $17,906,283.00
- ADAP $178,032,000.00
- Revenue This Year
- EPSM N/A
- ADAP N/A
- Revenue Next Year
- EPSM N/A
- ADAP $64.04
- P/E Ratio
- EPSM $94.28
- ADAP N/A
- Revenue Growth
- EPSM N/A
- ADAP 195.34
- 52 Week Low
- EPSM $4.23
- ADAP $0.20
- 52 Week High
- EPSM $6.34
- ADAP $1.48
- Technical
- Relative Strength Index (RSI)
- EPSM N/A
- ADAP 39.54
- Support Level
- EPSM N/A
- ADAP $0.20
- Resistance Level
- EPSM N/A
- ADAP $0.47
- Average True Range (ATR)
- EPSM 0.00
- ADAP 0.04
- MACD
- EPSM 0.00
- ADAP -0.00
- Stochastic Oscillator
- EPSM 0.00
- ADAP 39.43
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.